Quince Therapeutics (QNCX)
NASDAQ:QNCX
Want to see QNCX full AI Analyst Report?
QNCX Stock Chart & Stats
$1.37
-$0.07(-3.61%)
At close: 4:00 PM EST
$1.37
-$0.07(-3.61%)
Day’s Range― - ―
52-Week Range$0.79 - $45.49
Previous CloseN/A
Volume30.57K
Average Volume (3M)8.95M
Market Cap
$15.81M
Enterprise Value-$11.35M
Total Cash (Recent Filing)$18.16M
Total Debt (Recent Filing)$406.00K
Price to Earnings (P/E)―
Beta0.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,300,740
10 Day Avg. Volume21,870,698
30 Day Avg. Volume8,945,457
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap-0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit159.91
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety ProfileAnalyst notes the drug demonstrated a tolerable safety profile with no clinically meaningful safety concerns identified, which may reduce regulatory safety risk.
Patient RetentionAnalyst points out that all patients who completed the NEAT study elected to join the open-label extension, signaling strong patient confidence and potential for longer-term uptake.
Platform And Indication ExpansionAnalyst highlights eDSP's use of the AIDE technology platform and planned expansion into Duchenne muscular dystrophy and other indications, creating multiple development and commercial pathways.
Bears Say
Clinical Efficacy FailureAnalyst reports the Phase 3 NEAT study missed both the primary and key secondary endpoints, undermining the drug's efficacy case and core value proposition.
Development Halt And Strategic UncertaintyAnalyst notes management has halted clinical development of the program and is evaluating strategic options while conserving cash, creating uncertainty about the company's development path.
Financial Outlook And Analyst ReactionAnalyst cut the rating to Hold and removed expected revenue from the failed program, materially reducing projected future revenue and altering expense assumptions.
Quince Therapeutics News
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.79 and its highest was $45.49 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $15.81M.
When is Quince Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Quince Therapeutics’s earnings last quarter?
Currently, no data Available
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Overvalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 16,300,740 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quince Therapeutics
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Technical Analysis
Ownership Overview
50.74% Insiders
0.05% Mutual Funds
0.39% Other Institutional Investors
48.47% Public Companies and
Individual Investors